



BioCorporate profile downloaded from - <http://www.bioportfolio.com> on Thursday, November 26, 2009

AdProTech plc

[View the current AdProTech plc Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/131-AdProTech+plc.html)

(<http://www.bioportfolio.com/biocorporate/131-AdProTech+plc.html>)

Contact Details:

Chesterford Research Park, Little Chesterford
Safron Waldon
Essex
CB10 1XL
United Kingdom

Tel: 0870 444 6144
Fax: 0870 444 7244
Email: info@adpro.co.uk

AdProTech is a new biotechnology company dedicated to turning proteins into better drugs and better drug discovery tools. AdProTech recently opened its new laboratories in Royston near Cambridge, UK and is currently in a rapid growth phase. The company's focus is on innovative protein engineering and its current research programme is targeted towards the identification and development of novel protein therapeutics for the treatment of cardiovascular, inflammatory and autoimmune disorders. AdProTech has adopted a radical strategy which differentiates it significantly from other protein engineering based companies, in that post translational modification (PTM) of proteins is taken to be vital in the development of a working protein therapeutic agent. By attempting to mimic nature where PTM often dictates protein activity, AdProTech has successfully developed several proprietary technologies, which produce highly effective protein therapeutic agents. The most advanced of these is PRODAPTIN™ M which permits the engineering of a membrane "address" into a protein therapeutic agent to target it to the site where it is most effective.

Press Releases on AdProTech plc:

[SSL International plc Embraces TrackWise\(R\) Software for Global Quality and Compliance Efforts](#)

24th November,
2009

Sparta Systems, Inc.

HOLMDEL, N.J., Nov. 24 /PRNewswire/ -- Sparta Systems, Inc., the maker of TrackWise software and the market leader in enterprise quality and compliance solutions, today announced that SSL

[Aflac To Exchange Two Lloyds Banking Group Securities, Enhance Risk-Based Capital Ratio](#)

24th November, 2009

Aflac Incorporated

COLUMBUS, Ga., Nov. 24 /PRNewswire-FirstCall/ -- Aflac Incorporated (NYSE: AFL) announced today that the Lloyds Banking Group plc has accepted the exchange of two of its investment securities owned by

[Shire Submits European Marketing Authorization Application \(MAA\) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease](#)

24th November, 2009

Shire plc

DUBLIN, November 24 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has submitted a MAA to the European Medicines Agency SAN DIEGO, Nov. 23

[Victory Pharma, Inc. Announces Launch of NAPRELAN\(R\) Dose Card](#)

23rd November, 2009

Victory Pharma, Inc.

/PRNewswire/ -- Victory Pharma, Inc. ("Victory") announced today the launch of NAPRELAN® Dose Card, a further extension of Victory's NAPRELAN franchise. NAPRELAN

[Inimex Announces Appointment of New CEO](#)

23rd November, 2009

Inimex Pharmaceuticals Inc.

BURNABY, BC, Nov. 23 /PRNewswire/ - Inimex Pharmaceuticals, Inc. announced today that it has appointed Michael J. Abrams, Ph.D as its President and CEO. Abrams brings more than 25 years of drug

BioNews Results for AdProTech plc



- [AstraZeneca Seeks FDA Approval - Zibb.com](#)
Zibb: Nov 21 2009 1:11PM Matching: plc
- [FDA OKs Abilify for autism-linked irritability](#)
Kiplinger: Nov 21 2009 2:05AM Matching: plc
- [FDA OKs Abilify for autism-linked irritability](#)
Bioscience Technology Online: Nov 21 2009 1:14AM Matching: plc
- [SILENCE THERAPEUTICS PLC - Notice of AGM](#)
Individual.com: Nov 20 2009 3:32PM Matching: plc
- [Minster Pharma. PLC : Interim Results](#)
Investigate: Nov 20 2009 7:44AM Matching: plc
- [Saturday, November 21](#)
Plymouth Evening Herald: Nov 20 2009 2:20PM Matching: plc

- [Positive Final Lupuzor Trial Results](#)
Individual.com: Nov 20 2009 9:42AM Matching: plc
- [Hi-Shear Technology Corporation Announces Stockholder Approval of Merger Agreement with Chemring Group PLC](#)
Genetic Engineering News: Nov 20 2009 3:50PM Matching: plc
- [Global market for anti-depressants on a decline](#)
News-Medical.Net: Nov 20 2009 11:09AM Matching: plc
- [ImmuPharma PLC: Encouraging Final Phase IIb Results Seen with LUPUZOR\(TM\) in Systemic Lupus Erythematosus](#)
Individual.com: Nov 20 2009 9:42AM Matching: plc
- [ImmuPharma PLC: Encouraging Final Phase IIb Results Seen With LUPUZOR In Systemic Lupus Erythematosus](#)
Medical News Today: Nov 20 2009 8:02AM Matching: plc
- [Angel Biotechnology : Successful completion of MRHA](#)
Investigate: Nov 20 2009 7:43AM Matching: plc
- [Medical News: ImmuPharma PLC: Encouraging Final Phase IIb Results Seen With LUPUZOR In Systemic Lupus Erythematosus](#)
BioFind: Nov 20 2009 5:37AM Matching: plc
- [ImmuPharma PLC: Encouraging Final Phase IIb Results Seen With LUPUZOR In Systemic Lupus Erythematosus](#)
Medical News Today: Nov 20 2009 2:43AM Matching: plc
- [ImmuPharma PLC: Encouraging Final Phase IIb Results Seen with LUPUZOR in Systemic Lupus Erythematosus](#)
SmartBrief: Nov 20 2009 12:33AM Matching: plc

AdProTech plc Patents:



- 5859223- [Soluble CR1 derivatives](#)
- 5833989- [Soluble CR1 derivatives](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search

- engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

